Context: Uterine leiomyomas are the most common type of gynecologic tumor in women.
Currently available medical treatment options for leiomyoma, such as leuprolide, focus on symptom management (3) . These treatments can also cause notable adverse effects that limit their long-term use (3) . For leiomyomas that fail to respond to medical therapy, procedural options are available, including uterine fibroid embolization and magnetic resonance imaging-guided high-intensity focused ultrasound surgery. Myomectomy, the surgical removal of uterine leiomyoma, is a more invasive option and is associated with complications such as formation of pelvic adhesions, pelvic pain, Asherman syndrome, and weakening of the uterine myometrium with accompanying obstetric concerns (3) . Although myomectomy is useful for removing current leiomyoma, it does not prevent the formation of new ones. This is an important distinction because women who have had leiomyoma are more likely to form new tumors and need additional surgery in the future. There is a need for therapeutic options for uterine leiomyoma that not only treat the existing disease but also prevent formation of new tumors.
To provide better therapeutic options for uterine leiomyoma, we need to understand the underlying pathophysiology. Uterine leiomyomas are monoclonal tumors that originate from a single cell (5) . Leiomyoma stem cells (LSCs) arise within populations of myometrial stem cells as a result of gene mutations, such as MED12 or HMGA2 mutations (5) (6) (7) (8) . Our laboratory identified cell surface markers enriched in a leiomyoma side population of cells that has properties characteristic of stem cells (8) . On the basis of these markers, we identified three unique cell populations in leiomyoma: CD34 + (8) . We previously showed that CD34 + / CD49b + LSCs are essential for leiomyoma cell colony formation in vitro and tumor growth in vivo (8) .
In mammary tissue, the receptor activator of nuclear factor k-B ligand (RANKL)/ receptor activator of nuclear factor k-B (RANK) pathway has been identified as a key paracrine pathway through which progesterone initiates proliferation and differentiation of mammary stem cells that are progesterone receptor (PR)-negative. Mammary luminal epithelial cells, which are PR-positive, secrete RANKL in response to progesterone action (9) . RANKL then acts on its receptor RANK on the mammary stem cells, resulting in their differentiation into mammary epithelial cells and then milk-secreting acini (10, 11). We previously reported that, similar to mammary cells, the LIC population in uterine leiomyoma is PR positive, whereas LSCs lack PR expression (8) . In this study, we investigated the role of RANKL and its receptor in leiomyoma tumorigenesis and the potential role of its inhibitor RANK-Fc in preventing uterine fibroid cell proliferation and tumor growth. The ability to inhibit leiomyoma growth and, more importantly, to prevent the growth of new tumors at the stem cell level has immense implications for the treatment of leiomyoma.
Materials and Methods

Tissue collection
The institutional review board at Northwestern University approved this study. Informed consent was obtained before surgery. All patients were premenopausal women undergoing myomectomy or hysterectomy [mean age (6 standard deviation), 38 6 9 years; range, 28 to 49 years]. Women were excluded if they were receiving hormone treatment during the 6 months before surgery. Matched leiomyoma and myometrium tissue fragments from each patient were manually cut into 1-to 2-mm 3 pieces and snap frozen in liquid nitrogen for RNA extraction, explant culture, primary cell culture, or fluorescence-activated cell sorting (FACS). All experiments were performed with cells or tissue from at least three independent patients. The exact number of patient samples used for each experiment is reported in the figure legends. The following methods have been previously described by our research group (8) .
Cell preparation of human uterine leiomyoma
Leiomyoma fragments were manually cut into small pieces (1 to 2 mm 3 ), followed by incubation for 4 to 6 hours in calcium and magnesium-free Hanks balanced salt solution containing 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO), 1.5 mg/mL collagenase (Sigma-Aldrich), and 8 mg/mL DNase I (Sigma-Aldrich) at 37°C on a shaker. The digested tissue was filtered through a sterile 400-mm polyethylene mesh filter (BD Biosciences, San Jose, CA) to remove undigested tissues. For cell sorting procedures, the digested tissue was filtered again through a 40-mm cell strainer (BD Biosciences) to obtain a single-cell suspension.
Antibody staining for cell sorting procedures
To enrich the LSC population, we stained dissociated leiomyoma cells to identify specific cell surface markers (8) . Dissociated leiomyoma cells were resuspended at a concentration of 2 3 10 6 cells/mL in Hanks balanced salt solution containing 2% fetal bovine serum (staining medium). The cells were washed twice with staining medium and incubated on ice for 30 minutes with fluorescently labeled antibodies against CD45, CD34, or CD49b. All antibodies used are listed in Supplemental Table 1 . These antibodies were selected because previous data from our group described the role of these antibodies in enriching the leiomyoma side population and, specifically, LSCs (8) . CD45 staining was used to separate out peripheral blood leukocytes, and CD34 and CD49b were used to identify the different subpopulations of leiomyoma cells. After incubation with antibodies against CD45, CD34, and CD49b, the cells were washed three times and then incubated with 1 mg/mL propidium iodide (Sigma-Aldrich) to label nonviable cells. The cells were then subjected to cell sorting by using a FACSAria cell sorter (BD Biosciences 
Explant and cell culture studies
Tanos et al. (12) reported that PR signaling induced robust RANKL expression in the ex vivo tissue explant model, but it failed to induce RANKL in PR-positive breast cancer cell lines or in dissociated, cultured breast epithelial cells. This finding suggested that steroid hormone signaling, which relies on paracrine factors, can be studied adequately in the context of tissue samples with intact architecture. They also found that the cell viability (.90%) and hormone responsiveness with active cell proliferation in this model system remain very high after more than 6 days of ex vivo culture (12) . Therefore, for experiments designed to investigate the regulation of RANKL expression by progestin, we followed the same protocol with some modifications. Briefly, leiomyoma tissues from fresh myomectomies or hysterectomies were washed with phosphatebuffered saline, cut into small pieces (1 to 2 mm 3 ), and treated with vehicle or R5020 (PR agonist, 1 3 10 27 M) for 24 hours or 48 hours. Then, the explants were harvested for total RNA isolation. The 24-hour-treated explants were also digested and stained with CD34, CD49b, and CD45 for cell sorting, as described above, to determine the regulation RANKL gene expression by R5020 in each cell population. To determine the effect of RANK-Fc on leiomyoma cell function, we isolated leiomyoma smooth muscle cells from fresh fibroid tissues and maintained them in primary culture. The cells were then treated with Dulbecco phosphate-buffered saline (DPBS; Life Technologies, Carlsbad, CA) as vehicle, 50 ng/mL RANKL only (ProSpec, East Brunswick, NJ), 100 ng/mL RANK-Fc only (Amgen Inc., Thousand Oaks, CA), or both RANKL and RANK-Fc for 48 hours. RANK-Fc is a recombinant protein containing the murine extracellular domain of RANK fused to the Fc portion of murine IgG1.
Real-time polymerase chain reaction for RANKL and RANK messenger RNA expression Total RNA was extracted by using the RNeasy Mini Kit according to the manufacturer's instructions (Qiagen, Hilden, Germany). Total RNA was used to generate complementary DNA by using the qSCript complementary DNA synthesis kit (Quanta Biosciences, Beverly, MA). Quantitative real-time (qRT) polymerase chain reaction (PCR) to determine the gene expression of RANKL, RANK, and cyclin D1 was performed by using the ABI7900 with the TaqMan 2x Universal PCR master mix (Applied Biosystems, Foster City, CA). Primers used for PCR are listed in Supplemental Table 2 . The qRT-PCR machine was programmed as follows: 50°C for 2 minutes and 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. To determine relative transcript levels, the difference in cycle threshold (DCt) was calculated by subtracting the Ct for internal control from the Ct for target genes.
Immunoblotting analysis
Protein was extracted from the total or different leiomyoma cell population by using radioimmunoprecipitation assay buffer, followed by quantification using the bicinchoninic acid protein assay reagent (ThermoFisher Scientific, Waltham, MA) per the manufacturer's protocols. Then, the protein was diluted with reducing 4X LDS sample buffer (Life Technologies), electrophoresed on a 4% to 12% Novex Bis-Tris polyacrylamide precast gel (Life Technologies), and transferred onto polyvinylidene difluoride membrane. Incubation with primary antibodies (cyclin D1, RANKL, and RANK) (Supplemental Table 1 ) was performed at 4°C in 5% nonfat milk overnight. Anti-b-actin was used as a loading control. The membranes were then washed and incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies for 2 hours at room temperature. Detection was performed by using Luminata Crescendo horseradish peroxidase substrate (Millipore, Billerica, MA). Immunoblot was quantified by using ImageJ software (National Institutes of Health, Bethesda, MD).
Animal studies
Northwestern University's Animal Care and Use Committee approved all procedures involving animals. Dissociated cells from leiomyoma were suspended in rat-tail collagen (type 1) solution (BD Bioscience) at 10 6 cells/10 mL and cultured for 48 hours in floating cultures. Then, the cell pellets were grafted underneath the kidney capsules of ovariectomized nonobese diabetic-scid IL2Rg null mouse hosts (NSG, Jackson Laboratory, Bar Harbor, ME) supplemented with subcutaneous implantation of 50 mg progesterone plus 50 mg estradiol 60-day slowrelease pellets (Innovative Research of America Inc., Sarasota, FL) as a combination of estradiol and progesterone is indispensable for significant fibroid tumor growth and regeneration in the xenograft mouse model (8, 13) . A control group of mice was treated with vehicle (DPBS), whereas the treatment group was treated with RANK-Fc administered subcutaneously at 10 mg/kg twice a week (14, 15) . Mice were euthanized after 4 weeks of treatment, and images of regenerated tumors on the kidney surface were taken from the x-, y-, and z-axes by using a dissecting microscope connected to a computer with Leica Application Suite, version 3.8 software (Leica Microsystems Inc., Bannockburn, IL). Tumor volume was estimated by using the following formula: volume (mm 3 ) = 0.52 (derived from p/6) 3 length 3 width 3 height (mm) (16) . The fold-change from control to RANK-Fc-treated group was calculated.
Histological analyses
Paraffin-embedded mouse kidneys xenotransplanted with the total leiomyoma cell population were sectioned and immunohistochemistry (IHC) was performed by the Northwestern University Histology and Phenotyping Laboratory to detect proliferation marker Ki67. After deparaffinization, endogenous peroxidase was blocked with 3% hydrogen peroxide in doubledistilled water. Endogenous biotin was blocked with avidin, and nonspecific proteins were blocked with 5% normal donkey serum. The tissue sections were then incubated with the primary antibody against Ki67 (Supplemental Table 1 ), followed by incubation with the biotinylated secondary antibody and 3 0 -diaminobenzidine. Images were captured with a Leica microscope (Leica Microsystems Inc.). Cells staining positive for Ki67 were counted in 10 high-power fields. The fold-change from control to RANK-Fc treated group was calculated.
Statistical analysis
We analyzed data by using the Student t test when comparing two groups and a one-way analysis of variance, followed by multiple comparisons to compare three or more groups. We used GraphPad software, version 7.0 (La Jolla, CA). Values were considered statistically significant at P , 0.05.
Results
RANKL and RANK are differentially expressed in leiomyoma and myometrial tissue
To determine the role of RANKL/RANK pathway in the pathogenesis of leiomyoma, we first compared RANKL and RANK mRNA levels of leiomyoma and normal myometrial tissue. RANKL expression by qRT-PCR was significantly higher in leiomyoma than in myometrium (P , 0.001; n = 12) [ Fig. 1(A) ]. In contrast, RANK was preferentially expressed in myometrium compared with leiomyoma (P , 0.001; n = 12) [ Fig. 1(B) ].
RANK is preferentially expressed in LSCs and RANKL, in LICs
We hypothesized that, similar to mammary progenitor cells, the LIC population in leiomyoma expresses RANKL, which then acts on RANK expressed by LSCs to initiate growth and proliferation. To test this, we FACSsorted LSCs (CD34 + /CD49 + ), LICs (CD34 + /CD49b 2 ), and LDCs (CD34 2 /CD49b 2 ) and then performed qRT-PCR to compare RANK and RANKL expression in the different cell populations. RANKL expression was significantly higher in LICs than in LSCs and LDCs (P , 0.001; n = 5) [ Fig. 2(A) ]. Conversely, RANK expression was significantly higher in LSCs than in LICs and LDCs (P , 0.001; n = 5) [ Fig. 2(B) ]. These differences were recapitulated by immunoblotting analysis: The highest RANKL protein levels were observed in LICs, whereas the highest RANK protein levels were detected in LSCs [ Fig. 2(C) ].
Progestin induces RANKL but not RANK transcriptional activity
Leiomyomas are hormone-responsive tumors, so we next investigated whether progestin regulated RANKL expression in uterine leiomyoma. We treated tissue explants with the PR agonist R5020 and then extracted RNA to measure RANKL expression by qRT-PCR. Treatment of tissue explants with R5020 for 24 hours and 48 hours significantly increased RANKL expression compared with tissue explants treated with vehicle (24 hours, n = 3, P , 0.05 [ Fig. 3(A) ]; 48 hours, n = 3, P , 0.001 [ Fig. 3(B) ]). RANK expression did not differ between R5020-and vehicle-treated groups [ Fig. 3(C) ]. To determine whether R5020 stimulates RANKL expression preferentially in a particular cell population, we sorted three populations from explants treated with R5020 for 24 hours and measured RANKL expression in each population. We found that RANKL was significantly induced in LICs but not in LSCs or LDCs [ Fig. 3(D) ].
RANK-Fc inhibits expression of cell proliferative gene in vitro
Because RANKL has been shown to increase expression of cell cycle protein cyclin D1 in bone, we investigated whether it had a similar effect in leiomyoma cells (17) and whether this effect could be inhibited by RANKFc. Leiomyoma cells (total population) were cultured and separated into four treatment groups: vehicle, RANKL (50 ng/mL), RANK-Fc (100 ng/mL), or both RANKL and RANK-Fc. After 48 hours of treatment, protein was extracted and immunoblotting analysis was performed to quantify cyclin D1 expression. We found that RANKL treatment markedly increased the cyclin D1 protein level, which was blocked by cotreatment with RANK-Fc (Fig. 4) . RANK-Fc treatment alone did not significantly affect cyclin D1 expression.
RANK-Fc inhibits estrogen-and progesterone-responsive growth of leiomyoma tumors in vivo
Cell pellets consisting of the total leiomyoma cells were grafted underneath kidney capsules of ovariectomized NSG mouse hosts, and the mice were treated with vehicle or RANK-Fc (10 mg/kg subcutaneously twice a week for 4 weeks). Significantly smaller tumors were excised from mice treated with RANK-Fc compared with mice treated with vehicle (P , 0.05; n = 4 [ 
Discussion
Despite advances in our understanding of uterine leiomyoma, current treatment options are unable to prevent the formation of new uterine leiomyoma. Our study suggests a potential role for the RANKL/RANK pathway in leiomyoma tumorigenesis. Specifically, we found LSCs preferentially expressed RANK, indicating that these cells are able to respond to RANKL stimulation. We also demonstrated RANKL expression primarily by LIC, providing a potential paracrine mechanism by which LSCs are stimulated by LIC-derived RANKL. Most important, we found that the RANKL/RANK pathway inhibitor RANK-Fc decreased human leiomyoma tumor growth in vivo in the xenograft mouse model. This study evaluated a potential therapeutic option for uterine fibroids that targets the RANKL/RANK pathway in LSCs.
In mammary tissue, the RANKL/RANK pathway provides the key paracrine pathway by which progesterone induces proliferation and differentiation of stem cells into epithelial cells and subsequently milksecreting acini (10) . PR-positive mammary luminal epithelial cells secrete RANKL in response to progesterone. RANKL then acts on its receptor RANK on mammary stem cells to bring about proliferation and differentiation. Similarly, we found that RANKL expression in leiomyoma explants, preferentially in LICs, was increased in response to PR activation by R5020. However, transcription of cyclin D1, a RANKL target gene, was not concomitantly induced by R5020 in these explants (data not shown), which may be due to the absence of key in vivo conditions or cofactors in the in vitro model systems that we used. Treatment of leiomyoma cells directly with RANKL led to a significant increase in cyclin D1 protein expression, which was abolished by the presence of RANK-Fc; this finding suggests that RANKL can specifically regulate cyclin D1 expression in leiomyoma cells. In addition, RANKL is mainly expressed in LICs after depleting immune cells with anti-CD45 antibody [ Fig. 2(A) and 2(C) ], indicating that RANKL is derived primarily from fibroid cells but not infiltrating immune cells. Thus, our results suggest a potential paracrine interaction between LSCs and LICs, that is, LSCs are activated by LIC-derived RANKL.
The role of the RANKL/RANK pathway in cell proliferation and differentiation was first described in bone. Bone remodeling involves osteoblasts that build bone and osteoclasts that resorb bone (10) . Osteoblasts express RANKL, which acts on osteoclast precursor cells to induce their differentiation into mature osteoclasts to break down bone. Osteoprotegerin (OPG) is a decoy receptor for RANKL, and increased levels of OPG are associated with decreased bone resorption. In the hypoestrogenic postmenopausal state, OPG levels are reduced, leading to increased osteoclast differentiation and subsequent bone resorption (18) . Denosumab is a highly specific, fully human monoclonal antibody to RANKL and is used in the clinical treatment of osteoporosis (19) . However, the product is constrained in pregnancy in consideration of the side effects (20) . Our finding that RANK-Fc inhibited estrogen-and progesterone-responsive in vivo leiomyoma regeneration provides a potential alternative therapeutic strategy that may prevent new leiomyoma formation, and this represents a major advance in the clinical care of women affected by uterine leiomyoma. Further studies are needed to determine whether RANKFc can effectively reach all target stem cells within a complex whole organ structure to eliminate or inhibit the initiation of additional fibroid lesions.
Some strengths of our study include the use of human tissue and both in vitro and in vivo approaches to describe a potential paracrine pathway driving leiomyoma cell proliferation and tumor growth, and to test a potential therapeutic option for uterine leiomyoma that targets LSCs. Our study is also strengthened by the addition of a murine xenograft model to demonstrate the effects of RANK-Fc on fibroid growth in vivo, confirmed by Ki67 IHC. We performed in vivo experiments using immunodeficient mice, suggesting that the observed antitumor effect of RANK-Fc is likely mediated via direct effects on fibroid cells but not on infiltrating immune cells. The limitation of our study is the use of the total population of leiomyoma cells for the xenograft experiments, as opposed to just the LSC population. One future direction will be to repeat this experiment with specific combinations of the different leiomyoma cell populations and further characterize the RANKL/RANK paracrine pathway in the leiomyoma cell populations.
Conclusion
This study describes the role of the RANKL/RANK pathway in leiomyoma growth and a treatment targeting that pathway in leiomyoma stem cells. Our data show leiomyoma tumor growth suppression in a murine xenograft model after treatment with the RANKL/RANK pathway inhibitor RANK-Fc. These findings suggest that the RANKL/RANK system could serve as a potential target for prevention and treatment of uterine leiomyoma. Medications that can inhibit leiomyoma growth and prevent new leiomyoma would represent a major clinical advance in the management of uterine leiomyoma. Such a treatment could have important implications for women's reproductive health, future fertility, and quality of life.
